Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
• Age ≥ 18 years.
• Histopathology or cytology confirmed and recorded local progression or metastatic non-small cell lung cancer without systemic treatment.
• MET exon 14 skippign confirmed by an accredited local laboratory.
• ECOG 0 - 1.
• Predicted survival ≥ 12 weeks.
• Adequate bone marrow hematopoiesis and organ function
• Presence of measurable lesions according to RECIST 1.1.
• Subjects with stable brain metastases may be included in the study.
Locations
Other Locations
China
Yongchang Zhang
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Time Frame
Start Date: 2020-03-24
Estimated Completion Date: 2026-03-24
Participants
Target number of participants: 120
Treatments
Experimental: Cohort A: Target Therapy Group.
Patients with MET exon 14 skipping will be treated with First line crizotinib or savolitinib and other MET TKIs.
Experimental: Cohort B: Chemotherapy or Chemotherapy plus immune checkpoint inhibitor
Patients with MET exon 14 skipping will be treated with chemotherapy.
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital